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ABSTRACT
Introduction: Tocilizumab (TCZ) monotherapy
has been proven as an effective treatment for
rheumatoid arthritis (RA) in clinical trials.
However, there are limited data available
regarding the effectiveness of TCZ monotherapy
in real-world clinical settings in the United
States. The objective of this study was to
evaluate the impact of TCZ monotherapy on
disease activity and patient-reported outcomes
(PROs) in a US-based observational cohort of
patients with RA seen in routine clinical
practice.
Methods: Eligible patients had active RA, no
prior use of TCZ, and initiated TCZ as
monotherapy. Changes in disease activity and
PROs were assessed 1 year after TCZ initiation for
the overall cohort and stratified by number of
prior tumor necrosis factor inhibitors (TNFis; 0,
1, or C2). Primary outcomes were change in
ClinicalDiseaseActivity Index (CDAI); change in
patient global disease activity, pain, fatigue; and
the proportions of patients with improvement in
modified Health Assessment Questionnaire
(mHAQ), morning stiffness, and EQ-5D.
Results: Of 255 eligible TCZ monotherapy ini-
tiators, 9.4% were TNFi naive, 36.5% had one
prior TNFi, and 54.1% had C2 prior TNFis.
Clinical and PRO measures indicated that
patients were substantially impacted by their
disease at baseline. The median decrease in
CDAI from baseline to 1 year was 9.8 and
median patient global and pain scores improved
by 10 mm, indicative of clinically meaningful
improvement; the median fatigue score
improved by 5 mm. Approximately 26% of
patients reported clinically meaningful
improvement in mHAQ, 54% experienced
improvement in morning stiffness, and 20% to
36% experienced improvement in EQ-5D
domains (walking, self-care, usual activities,
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pain/discomfort, and anxiety/depression).
Improvements were similar across TNFi groups.
Conclusions: Patients with active, refractory RA
who initiated TCZ monotherapy experienced
improvements in both composite disease activ-
ity scores and PROs at 1 year, regardless of prior
TNFi exposure.
Funding: Corrona, LLC and Genentech.
Keywords: Biological therapy; Monotherapy;
Patient-reported outcome measures;
Rheumatoid arthritis; Tocilizumab
INTRODUCTION
Many patients with rheumatoid arthritis (RA)
experience diminished health-related quality of
life (HRQOL), as well as increased disability and
RA-related comorbidities [1, 2]. The goal of treat-
ment in patients with RA is to reduce disease
activity and improve patients’ HRQOL. In addi-
tion to traditional measures of clinical disease
activity, patient-reported outcomes (PROs) are
important measures in evaluating response to
therapy in patients with RA [3–5]. PROs take into
account HRQOL measures that impact patients’
experiences and activities of daily living, includ-
ing pain, fatigue, discomfort, emotional health,
and the ability to do usual physical activities.
Tocilizumab (TCZ) is a monoclonal antibody
that blocks the interleukin-6 receptor and is
approved for the treatment of patients with mod-
erate-to-severe RA who have had an inadequate
response to C1 disease modifying antirheumatic
drug (DMARD). TCZ can be administered as
monotherapy or in conjunction with conven-
tional synthetic DMARDs (csDMARDs), such as
methotrexate (MTX). Clinical studies have
demonstrated that TCZ has similar efficacy when
administered as monotherapy or in combination
with csDMARDs [6, 7]. In the USA, patients initi-
ating TCZ often have prior tumor necrosis factor
inhibitor (TNFi) exposure. It is estimated thatup to
40% of patients treated with a TNFi have an inad-
equate response [8–10]. BecauseTCZ isused later in
the line of therapy, patients initiating TCZ tend to
be older, with longer disease duration, and have
more disability and impairment than patients ini-
tiating TNFis [11].
TCZ monotherapy has been proven to be
effective for the improvement of RA disease
activity in multiple clinical trials [6, 12, 13], and
may be an effective treatment option for
patients with RA who cannot tolerate or prefer
not to use MTX. However, there are limited data
regarding the impact of TCZ monotherapy on
PROs. Additionally, clinical trial studies of
treatments for RA may not be predictive of
typical patient outcomes. Randomized clinical
trials usually include select patient populations
with high RA disease activity and may have
strict requirements with regard to prior RA
therapy exposure. Thus, findings from clinical
trials may be less generalizable to clinical prac-
tice than data from observational studies con-
ducted in real-world settings [14, 15]. The
objective of this study was to evaluate the
impact of TCZ monotherapy on clinical out-
comes and PROs in a large, US-based, observa-
tional cohort of patients with RA (Corrona),
both overall and stratified by prior TNFi
exposure.
METHODS
Study Setting
The Corrona registry has been previously
described in detail [16]. Briefly, the Corrona RA
registry (NCT01402661) is an independent,
prospective observational cohort that collects
longitudinal real-world data from patients and
their treating rheumatologists [17, 18]. The
registry includes patients recruited by 656 par-
ticipating rheumatologists from 169 private and
academic practice sites across 40 states in the
United States. As of June 30, 2016, data on
43,099 patients with RA have been collected.
Corrona’s database currently includes informa-
tion from 326,613 patient visits and 145,526.5
patient-years of follow-up observation, with a
mean duration of patient follow-up of
4.13 years (median, 3.33 years).
The study was conducted according to the
current (2013) version of the Declaration of
Helsinki. Ethics approvals for this study were
obtained from New England Independent
Review Board (IRB# 120160610) for private
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practice sites and local institutional review
boards of participating academic sites.
Study Analysis Population
Eligible participants were patients with RA in
the Corrona registry who were TCZ naive and
initiated TCZ as monotherapy between January
1, 2010 and March 31, 2015. Patients in Clinical
Disease Activity Index (CDAI) remission
(CDAI B 2.8) were excluded. Patients must have
had follow-up data available after TCZ initiation
with CDAI measurements at baseline (around
the time of TCZ initiation) and 1 year
(9–15 months) after treatment. Patients were
included in the analyses regardless of the addi-
tion of a csDMARD, switch to another biologic,
or discontinuation of TCZ without switching
prior to the 1-year follow-up visit.
For this study, data from Corrona were col-
lected from physician and patient question-
naires completed during routine clinical
encounters that occurred over the 1-year study
period. Data recorded at the time of clinical
encounter included use of csDMARDs and bio-
logics; 28-joint tender counts (TJC) and 28-joint
swollen counts (SJC); CDAI; 28-joint Disease
Activity Score based on erythrocyte sedimenta-
tion rate (DAS28-ESR); patient assessments of
global disease activity, pain, and fatigue; modi-
fied Health Assessment Questionnaire (mHAQ);
and EQ-5D.
Assessments and Outcomes
Disease activity and PROs at 1 year were asses-
sed using clinically validated measures. Disease
activity was evaluated using the median change
from baseline in CDAI and the level of disease
activity achieved at 12 months [19, 20]. As a
sensitivity analysis, we evaluated the median
change from baseline in DAS28-ESR and the
level of disease activity achieved at 12 months
in the subset of patients who had available
DAS28-ESR values.
PROs included patient global assessment of
disease activity, pain, and fatigue (0–100 mm on
a visual analog scale [VAS]) [21–24]; meaningful
improvement in mHAQ, defined as an
improvement[0.25 on a scale of 0 (without any
difficulty) to 3 (unable to perform) [25];
improvement in duration of morning stiffness
[26]; and EQ-5D, which records patient-reported
HRQOL across five domains (walking, self-care,
usual activities, pain/discomfort, and anxiety/
depression), the results of which can be exam-
ined using a summary index (0–1) or by indi-
vidual evaluation of each domain [27]. Each
EQ-5D domain is divided into three levels of
severity: severe disability, moderate disability,
or no disability. Improvement in individual
EQ-5D domains was defined as patients
improving from moderate disability to no dis-
ability or from severe disability to moderate or
no disability.
Statistical Analysis
Data on demographics, insurance status,
comorbid conditions, RA disease characteristics,
and RA medications were available for C99% of
patients. With respect to outcomes, disease
activity based on the CDAI, and PROs such as
patient global assessment, pain, and mHAQ
were available in[98% of patients. Fatigue and
the EQ-5D were added to the registry patient
questionnaire toward the end of 2010; thus,
patients who initiated TCZ earlier in 2010 did
not have baseline ascertainment of these two
PROs and were excluded from analyses exam-
ining change in these PROs over the study per-
iod. For all analyses, we excluded patients who
had missing data (baseline and/or follow-up) for
the outcome of interest.
Clinical outcomes and changes from base-
line in PROs were assessed at 1 year
(±3 months) and stratified by prior TNFi use (0,
1, or C2 prior TNFis). For patients with two
visits within the 9–15-month time window, the
visit closest to 12 months was used for the
1-year visit. For patients who discontinued TCZ
within 12 months and subsequently initiated
another biologic (defined as ‘‘switching’’), CDAI
was assessed using the last observation (before
the switch) carried forward. For patients who
discontinued TCZ within 12 months without
switching to another biologic, disease activity at
the 12-month visit was used for all analyses.
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Comparisons between patients who had
received one or C2 prior TNFi were analyzed
using v2 tests, Fisher exact tests, t tests, or Wil-
coxon-Mann–Whitney tests, as appropriate.
Additional subgroup analyses were conducted
to examine outcomes in TCZ monotherapy
initiators who remained on monotherapy for
12 months.
RESULTS
Patient Demographics and Clinical
Characteristics
A total of 500 patients with RA initiated TCZ as
monotherapy between January 1, 2010 and
March 31, 2015 (Fig. 1). Among patients exclu-
ded from the analysis, 242 were excluded due to
lack of follow-up information and/or missing
CDAI information at baseline or 12 months;
this group included patients who initiated TCZ
monotherapy late in the study window and
thus did not have a follow-up visit during the
study period, patients who initiated TCZ
monotherapy between Corrona visits and thus
did not have a baseline CDAI assessment, and
patients who did not have a follow-up visit
within the 9–15-month window of interest.
Three additional patients were excluded due to
CDAI B 2.8 at baseline. To address any potential
bias in the patient selection process, we evalu-
ated the demographics and clinical characteris-
tics of patients who were excluded from the
analysis. Patients who were excluded from the
analysis were similar with respect to age, sex, RA
disease duration, and baseline CDAI compared
with those who were included in the analysis.
Patient demographics and baseline disease
characteristics are described in Table 1. Of the
255 eligible TCZ monotherapy initiators who
were included in the analysis, 9.4% were TNFi
naive, 36.5% had received one prior TNFi, and
54.1% had received C2 prior TNFis. Most
patients were female (80.8%) and the overall
median (interquartile range [IQR]) age was 61
(49–69) years. The majority of patients (48.2%)
were in ACR functional class II (Table S1).
Patients who had received C2 prior TNFis were
younger than patients who had received one
prior TNFi (median [IQR] age, 58 [48–66] vs. 65
[55–73] years; P = 0.0002). A significantly
higher proportion of patients with C2 prior
TNFis were white and had a history of cardio-
vascular disease compared with patients with
one prior TNFi. The majority of patients (63.5%)
in the total study population had received C1
prior non-TNFi biologic. Of the patients who
had received C2 prior TNFis, 50.0% had also
received one prior non-TNFi and 18.8% had
received C2 prior non-TNFis.
Fig. 1 Summary of patient selection based on inclusion criteria. CDAI Clinical Disease Activity Index, PROs
patient-reported outcomes, TCZ tocilizumab
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Table 1 Baseline patient demographics, clinical characteristics, disease activity and PRO measures
All patients
N5 255
TNFi naive
n 5 24 (9.4%)
1 Prior TNFi
n5 93 (36.5%)
‡2 Prior TNFis
n5 138 (54.1%)
P valuea
Demographics and clinical characteristics
Age, median (IQR), years 61 (49–69) 62 (46–69) 65 (55–73) 58 (48–66) \0.001
Female, n (%) 206 (80.8) 20 (83.3) 72 (77.4) 114 (82.6) 0.329
White, n (%) 221 (86.7) 19 (79.2) 76 (81.7) 126 (91.3) 0.031
Duration of RA, median
(IQR), years
10 (5–18) 7 (4–11) 11 (6–18) 10 (6–19) 0.838
History of cardiovascular
disease, n (%)
12 (4.7) 2 (8.3) 1 (1.1) 9 (6.5) 0.046
History of hypertension,
n (%)
83 (32.5) 6 (25.0) 27 (29.0) 50 (36.2) 0.255
History of diabetes, n (%) 22 (8.6) 6 (25.0) 8 (8.6) 8 (5.9) 0.410
History of hyperlipidemia, n/
N (%)
14/231 (6.1) 0/22 (0.0) 9/85 (10.6) 5/124 (4.0) 0.063
ACPA seropositive, n/N (%) 57/93 (61.3) 3/8 (37.5) 25/44 (56.8) 29/41 (70.7) 0.183
RF seropositive, n/N (%) 85/138 (61.6) 6/13 (46.2) 33/54 (61.1) 46/71 (64.8) 0.673
No. of prior nonbiologic
DMARDs, median (IQR)
2 (1–3) 1 (0–2) 2 (1–2) 2 (1–3) 0.048
No. of prior non-TNFi biologics, %
0 36.5 29.2 46.2 31.2 0.032
1 49.4 66.7 44.1 50.0
C2 14.1 4.2 9.7 18.8
Clinical disease activity, median (IQR)
CDAI (0–76) 24.0
(16.7–34.0)
19.5
(13.0–34.5)
22.2 (14.0–30.0) 25.2 (19.0–34.1) 0.153
SJC (0–28) 6.0 (2.0–10.0) 4.0 (2.0–10.5) 6.0 (3.0–10.0) 6.0 (2.0–9.0) 0.555
TJC (0–28) 8.0 (3.0–13.0) 8.5 (3.5–12.5) 7.0 (2.0–12.0) 8.0 (4.0–14.0) 0.053
HRQOL measures, median (IQR)
Patient pain (0–100 mm) 60.0
(40.0–76.0)
58.5
(27.5–66.5)
60.0 (35.0–76.0) 65.0 (40.0–80.0) 0.466
Patient global (0–100 mm) 55.0
(40.0–75.0)
50.0
(22.5–75.5)
50.0 (30.0–70.0) 60.0 (40.0–75.0) 0.212
Patient fatigue (0–100 mm) 60.0
(33.0–80.0)
[n = 211]
70.0
(25.0–85.0)
[n = 19]
50.0 (23.5–80.0)
[n = 76]
65.0 (45.0–80.0)
[n = 116]
0.091
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Baseline Clinical Disease Activity
and PROs
Baseline disease activity and PROs are described
in Table 1. The median (IQR) CDAI score among
all patients was 24.0 (16.7–34.0); 8.2% of
patients had low disease activity (LDA; CDAI
[2.8 to B10), 25.7% had moderate disease
activity (MDA; CDAI[10 to B22), and 56.1%
had high disease activity (HDA; CDAI[22)
(Table S1). Patients had a median (IQR) SJC of 6
(2–10) and TJC of 8 (3–13). Disease activity
measures were similar between patients previ-
ously treated with one vs. C2 prior TNFis, with
baseline median (IQR) CDAI scores of 22.2
(14.0–30.0) and 25.2 (19.0–34.1), respectively
(P = 0.153). Of the patients who had received
one prior TNFi, 7.5% had LDA, 40.9% had MDA,
and 51.6% had HDA at baseline, while 8.0%,
31.1%, and 60.9% of patients who had received
C2 prior TNFis had LDA, MDA, or HDA,
respectively (Table S1). Patients with one prior
TNFi had a median (IQR) SJC of 6 (3–10) and
TJC of 7 (2–12), and those with C2 prior TNFis
had a median SJC of 6 (2–9) and TJC of 8 (4–14).
The overall baseline median (IQR) scores for
patient global assessment, pain, and fatigue
were 55.0 (40.0–75.0), 60.0 (40.0–76.0), and
60.0 (33.0–80.0) mm, respectively. The baseline
median (IQR) mHAQ score among all patients
was 0.6 (0.3–1.0), and patients reported a med-
ian (IQR) of 1 (0.5–2.5) h of morning stiffness.
The baseline median (IQR) EQ-5D score of the
total study population was 0.69 (0.59–0.78),
with the majority of patients reporting at least
some problems in walking (73.0%), self-care
(81.5%), usual activities (94.0%), and pain and
discomfort (94.0%); additionally, 43.7% of
patients reported at least some problems with
anxiety or depression (Tables 1 and S2).
Patients who had received one or C2 prior
TNFis had similar baseline median (IQR) scores
in patient global assessment (50.0 [30.0–70.0]
vs. 60.0 [40.0–75.0] mm; P = 0.212), pain (60.0
[35.0–76.0] vs. 65.0 [40.0–80.0] mm; P = 0.466),
fatigue (50.0 [23.5–80.0] vs. 65.0
[45.0–80.0] mm; P = 0.091), and mHAQ (0.5
[0.3–1.1] vs. 0.6 [0.3–0.9]; P = 0.761) (Table 1).
Patients in both groups experienced a median
duration of morning stiffness of 1 (IQR: one
prior TNFi, 0.59–0.78; C2 prior TNFis,
0.59–0.78) h and had a baseline median EQ-5D
score of 0.69 (IQR: one prior TNFi, 0.5–2.0; C2
prior TNFis, 0.5–3.00), with similar proportions
of patients in the groups receiving one or C2
prior TNFis reporting at least some problems
with walking (72.6% vs. 72.0%), self-care
(50.0% vs. 51.8%), usual activities (80.8% vs.
Table 1 continued
All patients
N5 255
TNFi naive
n 5 24 (9.4%)
1 Prior TNFi
n5 93 (36.5%)
‡2 Prior TNFis
n5 138 (54.1%)
P valuea
mHAQ (0–3) 0.63
(0.25–1.00)
[n = 251]
0.60
(0.13–0.81)
[n = 24]
0.50 (0.30–1.10)
[n = 92]
0.60 (0.30–0.90)
[n = 135]
0.761
Morning stiffness, hours 1.0 (0.5–2.5)
[n = 251]
1.0 (0.5–2.5)
[n = 24]
1.0 (0.5–2.0)
[n = 90]
1.0 (0.5–3.0)
[n = 137]
0.385
EQ-5D (0–1) 0.69
(0.59–0.78)
[n = 193]
0.69
(0.59–0.74)
[n = 16]
0.69 (0.59–0.78)
[n = 67]
0.69 (0.59–0.78)
[n = 110]
0.865
a The P value applies to the comparison between patients with one prior TNFi vs. those with C 2 prior TNFis
ACPA anti-cyclic citrullinated peptide antibody, CDAI Clinical Disease Activity Index, DMARD disease-modifying anti-
rheumatic drug, HRQOL health-related quality of life, IQR interquartile range, mHAQ modiﬁed Health Assessment
Questionnaire, RA rheumatoid arthritis, RF rheumatoid factor, SJC swollen joint count, TJC tender joint count, TNFi
tumor necrosis factor inhibitor
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80.8%), pain/discomfort (94.5% vs. 94.6%), and
anxiety/depression (41.1% vs. 44.8%) (Tables 1
and S2).
Disease Activity 1 Year After Initiation
of TCZ Monotherapy
After 1 year (median [IQR], 12 [11–13] months)
of follow-up, 109 patients (42.7%) were still
receiving TCZ as monotherapy, 66 (25.9%) had
switched to another biologic, 48 (18.8%) were
receiving TCZ in combination with a csDMARD,
and 32 (12.5%) discontinued TCZ without
switching (Table S3). The primary reason for
discontinuation or switching was lack of effi-
cacy (62.9%); 19.4% of patients discontinued or
switched due to issues with safety and 4.8% for
a combination of efficacy and safety reasons.
The rates of switching to another biologic,
adding a csDMARD, and discontinuation were
similar across TNFi groups (Table S3).
The overall median (IQR) decrease in CDAI
from baseline to 1 year was 9.8 (8.2–11.4)
(Fig. 2a). At 1 year, 11.4% of patients were in
remission, 31.0% had LDA, 31.4% had MDA,
and 26.7% had HDA (Fig. 2b). Improvement in
CDAI and achievement of LDA or remission
were similar across the TNFi groups (Fig. 2). The
median (IQR) change from baseline in CDAI
was 10.6 (7.7–13.6) in patients who had
received one prior TNFi and 9.6 (7.6–11.6) for
those who had received C2 prior TNFis
(P = 0.547). Approximately 11% of patients in
both groups were in remission at 1 year; in the
group with one prior TNFi, 34.4%, 32.2%, and
22.6% of patients had LDA, MDA, and HDA,
respectively, while in the group with C2 prior
TNFis, 28.3%, 32.6%, and 28.3% of patients had
LDA, MDA, and HDA, respectively. Similar
results were seen in the population of patients
with available DAS28-ESR (Figure S1).
Among those patients who persisted on TCZ
monotherapy over 12 months (n = 109), the
median (IQR) decrease in CDAI was 12.6
(3.3–19.0). At 12 months, 14.7% of patients
were in remission, 33.9% had achieved LDA,
33.9% had MDA, and 17.4% had HDA.
PROs 1 Year After Initiation of TCZ
Monotherapy
Improvement from baseline was observed in
all PRO measures. Overall, the median (IQR)
improvement from baseline in both patient
Fig. 2 Improvement in clinical outcomes 1 year after
initiation of TCZ monotherapy, overall and stratiﬁed by
prior TNFi experience. a Median change from baseline in
CDAI. b Shifts in CDAI category from baseline to 1 year.
Remission was deﬁned as CDAI B2.8; low disease activity
as CDAI[2.8 to B10; moderate disease activity as CDAI
[10 to B22; and high disease activity as CDAI [22.
CDAI Clinical Disease Activity Index, TCZ tocilizumab,
TNFi tumor necrosis factor inhibitor
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global assessment and pain was 10 (-5 to 30)
mm; median (IQR) improvement in fatigue
was 5 (-10 to 23) mm (Fig. 3a; Table S4).
Patients had a median percent improvement
from baseline of 23.1% in patient global
assessment, 22.2% in pain, and 10.8% in
fatigue at 12 months. In the total study pop-
ulation, 26.1% of patients experienced clini-
cally meaningful improvement in mHAQ
1 year after initiating TCZ monotherapy
(Fig. 3b). Approximately half (54.0%) of
patients in the total study population had
improvement in morning stiffness, with
19.4% of patients achieving a reduction of
[60 min and 34.6% achieving a reduction of
1 to 60 min (Fig. 3c). Patients also experi-
enced improvement in all EQ-5D domains,
with 20.8% of patients reporting at least some
improvement in walking, 36.2% in self-care,
26.7% in usual activities, 21.3% in pain/dis-
comfort, and 33.0% in anxiety/depression
(Fig. 4).
Fig. 3 Improvement in PROs 1 year after initiation of
TCZ monotherapy overall and stratiﬁed by prior TNFi
experience. a Median improvement from baseline in
patient global assessment, pain, and fatigue scores. The
full data set is described in Table S3. b Proportion of
patients who experienced clinically meaningful improve-
ment in mHAQ, deﬁned as an improvement[0.25 [23].
Data are the percentage of patients reporting improvement
among those patients who reported difﬁculty in each
measure at baseline. c Proportion of patients who
experienced reduction in duration of morning stiffness.
mHAQ modiﬁed Health Assessment Questionnaire, TCZ
tocilizumab, PROs patient-reported outcomes, TNFi
tumor necrosis factor inhibitor
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Patients who remained on TCZ monother-
apy over the 12-month study period had med-
ian improvement from baseline of 15.0
(0–33.0) mm for patient global assessment, 12.0
(0–34.0) mm for pain, and 5.0 (-9.0 to 25.0)
mm for fatigue. Furthermore, 53.3% of these
patients had a reduction in morning stiffness.
Patients in this group also experienced
improvement in the EQ-5D domains, with
20.6% having an improvement in walking,
36.2% in self-care, 32.9% in usual activities,
24.4% in pain and discomfort, and 28.6% in
anxiety/depression.
Improvements in patient global assessment,
fatigue, mHAQ, and morning stiffness were
similar across TNFi groups (Fig. 3 and Table S4).
However, patients with C2 prior TNFis had sig-
nificantly greater improvement in median (IQR)
pain score than patients with one prior TNFi (15
[0–35] vs. 8 [-5 to 25] mm; P = 0.050). A sig-
nificantly higher proportion of patients with
one prior TNFi experienced improvement in the
EQ-5D domains of walking and usual activities
than did patients with C2 prior TNFis (Fig. 4;
walking, 35.3 vs. 10.8%; P = 0.001; usual activ-
ities, 35.6 vs. 18.9%; P = 0.022).
DISCUSSION
In this study, patients with active, refractory RA
who had an inadequate response to prior
csDMARDs and/or TNFis and newly initiated
TCZ monotherapy experienced substantial
improvement in clinical disease activity and
HRQOL 1 year after TCZ initiation, regardless of
prior TNFi exposure. At baseline, the majority of
patients were in high disease activity and
reported substantial impacts of their disease on
HRQOL. As indicated by the change from
baseline in median CDAI (9.8), [50% of
patients experienced clinically important
improvement in disease activity (minimal
Fig. 4 Improvement in EQ-5D categories at 1 year among
TCZ initiators, overall and stratiﬁed by prior TNFi
experience. aPercentage of patients reporting improvement
among those patients who reported difﬁculty in each
measure at baseline. bImprovement in the EQ-5D domains
was deﬁned as either an improvement from moderate to
no disability, or from severe disability to moderate or no
disability. * P\0.05. The P value applies to the compar-
ison between patients with one prior TNFi vs. those with
C2 prior TNFis. TCZ tocilizumab, TNFi tumor necrosis
factor inhibitor
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clinically important difference [MCID] C 6) at
1 year [20]. Furthermore,[40% of patients were
in remission or had LDA as assessed by CDAI.
Over half of patients reported clinically mean-
ingful improvement in patient global assess-
ment and pain (MCID C 10 mm), as indicated
by median improvement from baseline in both
PROs of 10 mm. Approximately 26% of patients
experienced clinically meaningful improve-
ment in mHAQ (MCID[0.25), and the major-
ity of patients (54%) experienced at least some
improvement in morning stiffness. Addition-
ally, 20% to 36% of patients experienced
improvement in EQ-5D domains (walking,
self-care, usual activities, pain/discomfort, and
anxiety/depression). Improvements in disease
activity and PROs were mostly similar across
TNFi groups; however, a significantly higher
proportion of patients who had received one
prior TNFi experienced improvement in walk-
ing and usual activities of daily living than did
patients who had received C2 prior TNFis, while
patients with C2 prior TNFis had significantly
greater improvement in pain than those with
one prior TNFi.
Clinical trials have demonstrated the efficacy
of TCZ in the improvement of both disease
activity and HRQOL. In ACT-RAY, which eval-
uated the efficacy and safety of TCZ
monotherapy compared with that of
TCZ ?MTX in patients with an inadequate
response to MTX, 15.6% of patients treated with
TCZ monotherapy achieved CDAI remission
and patients experienced significant improve-
ments from baseline in mean patient global
assessment (40.9) and pain (38.4) at 1 year [28].
The improvements observed in our study are
comparable but slightly lower than those
observed in ACT-RAY, with 11% of patients
achieving CDAI remission and mean improve-
ments from baseline in patient global assess-
ment and pain of 12.0 and 13.9, respectively. Of
note, patients in ACT-RAY had higher disease
activity at baseline, as indicated by higher mean
SJC and TJC, than patients in our study (15.3 vs.
6.0 and 26.6 vs. 8.0, respectively). Because
baseline disease activity levels in real-world
settings tend to be lower than those reported in
randomized trials, there is the potential for a
‘‘floor effect’’ of clinical response; that is, it is
more of a numerical challenge to improve a
disease activity metric if a patient has a lower
disease burden at baseline compared with those
in clinical trials. Additionally, the majority of
patients in our study had prior TNFi experience
whereas those in ACT-RAY were biologic naive.
Due to the real-world setting, it is possible that
the patient population in our study was more
refractory to biologic therapy at initiation of
TCZ compared with those in ACT-RAY.
There are few large, observational, real-world
studies evaluating the effectiveness of TCZ
monotherapy in improvement of both disease
activity measures and PROs. In an observational
cohort study of the Tsurumai Biologics Com-
munication Registry in Japan, the proportion of
patients with DAS28-ESR \2.6 increased from
2% at baseline to 37% at 1 year after initiating
TCZ monotherapy and patients experienced a
mean improvement from baseline in patient
global assessment of approximately 15 mm [29].
Similarly, the proportion of patients with
DAS28-ESR\2.6 in our study increased from 7%
at baseline to 39% at 1 year after initiating TCZ
monotherapy, and patients experienced a
median improvement from baseline in patient
global assessment of 10 mm. Importantly,
baseline disease characteristics were similar
between patients from the Tsurumai Biologics
Communication Registry and patients in this
study, including disease duration (8.7 vs.
10.0 years), SJC (7.0 vs. 6.0), and TJC (8.7 vs.
8.0) [29].
These data suggest that in clinical practice,
initiation of TCZ monotherapy at any stage of
the RA treatment regimen may improve clinical
outcomes and HRQOL. In this population of
patients with established and severe RA,
patients demonstrated substantial and clinically
meaningful improvements in disease activity
and HRQOL with TCZ monotherapy, regardless
of prior TNFi exposure. At baseline, the majority
of patients reported problems with walking,
self-care, usual activities, pain/discomfort, and
anxiety/depression. One year after initiating
TCZ monotherapy, 20% to 36% of patients
experienced at least some improvements in
these HRQOL measures, even those with prior
exposure to multiple TNFis. Of note, patients
who received TCZ earlier in the line of
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treatment (one prior TNFi) had better response
with respect to improvement in walking and
usual activities of daily living than those who
had received C2 prior TNFis. These data may
suggest that switching to TCZ earlier in the
course of disease (i.e., after an initial inadequate
response to a TNFi) may be a more effective
strategy than switching to another TNFi in
terms of improvement in HRQOL.
The Corrona registry provides a unique
opportunity to examine clinical outcomes in a
large, population-based cohort of patients with
established RA treated with TCZ monotherapy
in routine clinical practice. The observational
nature of the study and the inclusion of patients
regardless of disease duration, disease severity or
prior medication history (except prior use of
TCZ) allowed evaluation of the efficacy of TCZ
monotherapy in routine management of RA.
Additionally, examination of both clinical dis-
ease activity outcomes and PROs in the same
real-world cohort of patients provides a more
holistic view of the efficacy of TCZ in the
management of RA.
A general limitation of real-world observa-
tional studies is the concern that patients
enrolled in registries may not be representative
of patients observed elsewhere in general prac-
tice. However, a previous study found Medicare
patients in the Corrona registry were similar to
the national Medicare RA population in terms
of demographic characteristics, suggesting that
data from patients in Corrona may be general-
izable to the population of patients with RA in
the United States [18]. In this study cohort, the
sample size for TNFi-naive patients was small,
which may be due in part to the use of TCZ
more often as a second-line biologic following
an inadequate response to C1 TNFi [8]. Addi-
tionally, the effects of disease duration, patient
adherence to treatment, and treatment persis-
tency were not assessed in this study. Specifi-
cally, the sample sizes for patients who switched
from TCZ to a new biologic, added a csDMARD,
or discontinued TCZ without switching were
small, which inhibited subanalyses comparing
outcomes in these patient groups with patients
who continued TCZ monotherapy through the
1-year study endpoint. Furthermore, follow-up
time was limited to 1 year; longer follow-up is
necessary to assess the long-term effectiveness
of TCZ monotherapy in managing RA disease
activity and HRQOL. Finally, this study was an
observational study that assessed data from
patients with RA treated with TCZ monother-
apy without a control group; therefore, no
conclusions can be drawn in comparison to
other available treatment options for RA.
CONCLUSIONS
In conclusion, patients with active, refractory
RA and an inadequate response to csDMARDs
and/or TNFis who initiated TCZ monotherapy
experienced significant improvements in dis-
ease activity and HRQOL. This study demon-
strated the efficacy of TCZ monotherapy in
patients with RA, regardless of prior TNFi
exposure. In addition, our results demonstrate
that using validated measures of disease activity
in combination with PROs provides a more
holistic view of the efficacy of treatment with
TCZ monotherapy in patients with RA cared for
in typical clinical practice.
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